Latest stories on AIM
AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcript
Seeking Alpha53 · neutralproduct/pr
AIM ImmunoTech Highlights Ampligen’s Emerging Ebola Treatment Potential
TipRanks58 · neutralproduct/pr
3 Penny Stocks Drawing Market Attention, 6/2/26
TipRanks53 · neutralgeneral
AIM ImmunoTech Highlights Ampligen’s Ebola Potential After WHO Emergency—Pre-Clinical Data Shows 100% Survival in Study
MarketChameleon61 · neutralproduct/pr
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
Business Insider58 · neutralgeneral
AIM ImmunoTech Strengthens Equity Position and Financial Flexibility
TipRanks58 · neutralgeneral